113117-17-2

Upstream product

• 36239-09-5 ethyl chlorocarbonylacetate 
• 873-74-5 4-Aminobenzonitrile 

Downstream Products

• 1100767-21-2 2-[4-cyano-phenylcarbamoyl]-acetic acid 
• 1100767-24-5 N-[4-(N-hydroxycarbamimidoyl)-phenyl]-malonamic acid ethyl ester 
• 1100768-41-9 N-(4-carbamimidoyl-phenyl)-N'-{1-[3-(5-chloro-thiophen-2-yl)-4-(morpholine-4-sulfonyl)-phenyl]-ethyl}-malonamide trifluoroacetate 
• 1100769-10-5 N-(4-carbamimidoyl-phenyl)-N'-{(S)-1-[4-(morpholine-4-sulfonyl)-3-trifluoromethyl-phenyl]-ethyl}-malonamide trifluoroacetate 
• 1100768-22-6 4-(4-{1-[2-(4-carbamimidoyl-phenylcarbamoyl)-acetylamino]-ethyl}-phenyl-carbamoyl)-piperidine-1-carboxylic acid tert-butyl ester trifluoroacetate 
• 1100768-46-4 N-(4-carbamimidoyl-phenyl)-N'-{1-[4-(morpholine-4-sulfonyl)-3-thiazol-2-yl-phenyl]-ethyl}-malonamide trifluoroacetate 
• 1100768-24-8 N-(4-carbamimidoyl-phenyl)-N'-{1-[4-(piperidin-3-yloxy)-3-trifluoromethyl-phenyl]-ethyl}-malonamide trifluoroacetate 
• 1100768-36-2 N-(4-carbamimidoyl-phenyl)-N'-{1-[3-(5-chloro-thiophen-2-yl)-4-(tetrahydro-pyran-4-yloxy)-phenyl]-ethyl}-malonamide trifluoroacetate 
• 1100768-15-7 N-(1-{3-bromo-4-[(piperidine-4-carbonyl)-amino]-phenyl}-ethyl)-N'-(4-carbamimidoyl-phenyl)-malonamide trifluoroacetate 
• 1100768-04-4 N-(4-carbamimidoyl-phenyl)-N'-{1-[4-(pyridine-4-sulfonyl)-3-trifluoromethyl-phenyl]-ethyl}-malonamide trifluoroacetate 
• 1100767-43-8 5-(2-bromo-4-{1-[2-(4-carbamimidoyl-phenylcarbamoyl)-acetylamino]-ethyl}-phenoxy)-nicotinic acid trifluoroacetate 
• 1100768-32-8 N-{1-[3-bromo-4-(morpholine-4-carbonyl)-phenyl]-ethyl}-N'-(4-carbamimidoyl-phenyl)-malonamide trifluoroacetate 
• 1100767-69-8 N-(4-carbamimidoyl-phenyl)-N'-(1-{4-[(2-methoxy-ethyl)-methyl-amino]-3-trifluoromethyl-phenyl}-ethyl)-malonamide trifluoroacetate 
• 1100768-19-1 N-(4-carbamimidoyl-phenyl)-N'-(1-{4-[(piperidine-4-carbonyl)-amino]-phenyl}-ethyl)-malonamide trifluoroacetate 

Relevant academic research and scientific papers

MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY

The present invention relates to compounds of the formula (I). The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are inhibitors of the blood clotting enzymes, especially factor VIla and can in general be applied in conditions in which an undesired activity of factor VIla is present or for the cure or prevention of which an inhibition of factor VIla is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.